Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM) from its SEC filings: 2022 revenue $0 (-100% vs the year before), free cash flow -$127.8 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2022) | $0 |
| Revenue growth | -100% |
| Net income | $111.2 million |
| Free cash flow | -$127.8 million |
| Diluted EPS | $2.38 |
| Cash | $78.6 million |
| Share count, 1 year | +9% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.